[Asia Pacific Pharmaceuticals: Subsidiary signs letter of intent for cooperation in innovative drug technology transactions] On October 13, Asia Pacific Pharmaceuticals (002370.SZ) announced that the company's wholly-owned subsidiary Shengyao Optical Research and Quzhou Fudan Research Institute signed a letter of intent for cooperation in innovative drug technology transactions, and plans to introduce the technological achievements of Class 1.1 small molecule innovative drugs "a BODIPY photosensitizer for acne treatment". The transaction price includes RMB 25 million in R&D and approval milestone payments, a cumulative commercialization milestone payment of no more than RMB 40 million, and a sales share of 2% of the annual net sales after the product is launched, with a maximum cumulative total of no more than RMB 100 million. This cooperation still needs to complete due diligence and implement decision-making procedures, and there are uncertainties.